article thumbnail

Moderna receives $176 million from BARDA for mRNA influenza vaccines

STAT

Moderna has been awarded $176 million by the Biomedical Advanced Research and Development Authority to accelerate development of messenger RNA-based pandemic influenza vaccines, the company announced in a statement Tuesday. Read the rest…

Vaccines 142
article thumbnail

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio tech

pharmaphorum

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. Non-injectables remove the need for health professional-led immunisation programmes, making widespread vaccine roll-outs quicker and easier and more affordable,” Channon told pharmaphorum.

Vaccines 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation

pharmaphorum

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults.

article thumbnail

Brazil grants authorisation for Sinovac’s Covid-19 vaccine in children

Pharmaceutical Technology

The Brazilian Health Regulatory Agency (Anvisa) has granted emergency use authorization for Sinovac Biotech’s Covid-19 vaccine, CoronaVac, in children aged three to five years. Subjects in this age group can receive the same vaccine dosage authorised in patients aged six to 17 years, as well as adults.

article thumbnail

The mRNA-1273 Vaccine at 25-?g Dosage May Protect Infants, Young Children Against Omicron

Pharmacy Times

The Moderna mRNA-1273 vaccine was found to be effective for more than 50% of children aged 6 to 23 months.

Dosage 50
article thumbnail

Innovative vaccine demonstrates sustained malaria immunisation in pregnancy

European Pharmaceutical Review

Two trials ( Phase I and Phase II ) of a vaccine given to healthy adults from Mali has demonstrated its potential as a safe and effective way to immunise against malaria, prior to and during pregnancy. In one trial, the PfSPZ vaccine was evaluated in 300 healthy women ages 18 to 38 years.

article thumbnail

AZ mulls trial of new COVID-19 vaccine dose as UK regulator begins review

pharmaphorum

AstraZeneca is to run an additional global trial to test its COVID-19 vaccine at a lower dosage, as the UK regulator begins to review trial data. Health secretary Matt Hancock has asked the UK’s regulator the Medicines and Healthcare products Regulatory Agency (MHRA) to begin its review of the vaccine.